Lung Cancer Biomarkers Present Status and Future Developments
Lung Cancer Biomarkers Present Status and Future Developments
复制标题
DOI：
10.5858/arpa.2013-0319-cr
复制
发表时间：
2013-09-01
影响因子：
4.6
通讯作者：
Olsen, Randall J.
中科院分区：
文献类型：
--
作者：
Cagle, Philip T.;Allen, Timothy Craig;Olsen, Randall J.
“选择EGFR和ALK酪氨酸激酶抑制剂的肺癌患者的分子检测指南：美国病理学家学会、国际肺癌研究协会和分子病理学协会的指南”的出版物现已为第一代肺癌酪氨酸激酶抑制剂的生物标志物检测提供了指南。生物标志物检测永远改变了病理学家在肺癌患者管理中的作用。目前，肺癌精准医学中尚未解决的问题将通过开发新的生物标志物检测、新药和新的检测技术以及提高生物标志物检测的成本效益比来解决。
The publication of the "Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology" has now provided a guideline for biomarker testing for first-generation lung cancer tyrosine kinase inhibitors. Biomarker testing has forever altered the role of pathologists in the management of patients with lung cancer. Current, unresolved issues in the precision medicine of lung cancer will be addressed by the development of new biomarker tests, new drugs, and new test technologies and by improvement in the cost to benefit ratio of biomarker testing.